First Trust Advisors LP Purchases 44,912 Shares of Cellebrite DI Ltd. $CLBT

First Trust Advisors LP raised its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 49.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 136,409 shares of the company’s stock after purchasing an additional 44,912 shares during the period. First Trust Advisors LP’s holdings in Cellebrite DI were worth $1,880,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its holdings in shares of Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares in the last quarter. Advisory Services Network LLC purchased a new position in shares of Cellebrite DI during the 3rd quarter valued at about $40,000. CWM LLC raised its holdings in shares of Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after buying an additional 889 shares in the last quarter. First Horizon Corp lifted its position in Cellebrite DI by 421.8% in the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after buying an additional 2,337 shares during the last quarter. Finally, Vestcor Inc bought a new stake in Cellebrite DI in the 3rd quarter worth approximately $70,000. Institutional investors own 45.88% of the company’s stock.

Insider Buying and Selling

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. The trade was a 2.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David Barter sold 41,734 shares of Cellebrite DI stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the transaction, the chief financial officer directly owned 334,219 shares in the company, valued at $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 158,191 shares of company stock worth $2,479,438 in the last ninety days. 5.70% of the stock is owned by insiders.

Cellebrite DI Trading Up 3.6%

CLBT opened at $16.01 on Friday. Cellebrite DI Ltd. has a 12 month low of $11.02 and a 12 month high of $19.98. The business’s 50-day moving average price is $14.55 and its 200-day moving average price is $14.11. The company has a market cap of $3.99 billion, a P/E ratio of 57.18, a P/E/G ratio of 1.98 and a beta of 1.18.

Wall Street Analyst Weigh In

A number of brokerages have commented on CLBT. DA Davidson increased their price target on shares of Cellebrite DI from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Finally, Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $21.80.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.